Review



polyclonal antibodies against myog  (Santa Cruz Biotechnology)


Bioz Verified Symbol Santa Cruz Biotechnology is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Santa Cruz Biotechnology polyclonal antibodies against myog
    Expression levels of various markers in differentiated hPSC-derived myogenic progenitors treated with rat sera. The expression of Pax7 and Myogenin <t>(MyoG)</t> proteins were analyzed in the differentiated cells for 3 days with 20% young or aged rat sera. (A) The type of supplemented sera did not alter the percentage of total myogenic cells (expressing PAX7, MyoG, or both) (Student’s t -test, t = 1.115, df = 10, p = 0.291). There was no difference in the number (B) and proportions (C) of quiescent, activating and activated myogenic progenitors out of total cells (represented by cells expressing PAX7 + /MyoG − , PAX7 + /MyoG + and PAX7 − /MyoG + , respectively) (2-way ANOVA, F 1,30 = 1.958, p = 0.172 for (B) ; Student’s t -test, t < 0.001 df = 2, p > 0.999 for (C) . (D) On Day 7 of terminal differentiation, cells supplemented with aged rat sera showed an increased level of a cell proliferation marker Ki67 (t = 9.357, df = 10, p < 0.001; by unpaired two-tailed Student’s t-test). (E) Western blot analysis showed increased cyclin B1 and CDK 2 expression in hPSC-derived myogenic progenitors differentiated in 20% aged rat sera for 2 weeks. Beta-actin served as loading control. n = 6 for each group * p < 0.05.
    Polyclonal Antibodies Against Myog, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/polyclonal antibodies against myog/product/Santa Cruz Biotechnology
    Average 90 stars, based on 1 article reviews
    polyclonal antibodies against myog - by Bioz Stars, 2026-05
    90/100 stars

    Images

    1) Product Images from "Cellular and transcriptomic changes by the supplementation of aged rat serum in human pluripotent stem cell-derived myogenic progenitors"

    Article Title: Cellular and transcriptomic changes by the supplementation of aged rat serum in human pluripotent stem cell-derived myogenic progenitors

    Journal: Frontiers in Cell and Developmental Biology

    doi: 10.3389/fcell.2024.1481491

    Expression levels of various markers in differentiated hPSC-derived myogenic progenitors treated with rat sera. The expression of Pax7 and Myogenin (MyoG) proteins were analyzed in the differentiated cells for 3 days with 20% young or aged rat sera. (A) The type of supplemented sera did not alter the percentage of total myogenic cells (expressing PAX7, MyoG, or both) (Student’s t -test, t = 1.115, df = 10, p = 0.291). There was no difference in the number (B) and proportions (C) of quiescent, activating and activated myogenic progenitors out of total cells (represented by cells expressing PAX7 + /MyoG − , PAX7 + /MyoG + and PAX7 − /MyoG + , respectively) (2-way ANOVA, F 1,30 = 1.958, p = 0.172 for (B) ; Student’s t -test, t < 0.001 df = 2, p > 0.999 for (C) . (D) On Day 7 of terminal differentiation, cells supplemented with aged rat sera showed an increased level of a cell proliferation marker Ki67 (t = 9.357, df = 10, p < 0.001; by unpaired two-tailed Student’s t-test). (E) Western blot analysis showed increased cyclin B1 and CDK 2 expression in hPSC-derived myogenic progenitors differentiated in 20% aged rat sera for 2 weeks. Beta-actin served as loading control. n = 6 for each group * p < 0.05.
    Figure Legend Snippet: Expression levels of various markers in differentiated hPSC-derived myogenic progenitors treated with rat sera. The expression of Pax7 and Myogenin (MyoG) proteins were analyzed in the differentiated cells for 3 days with 20% young or aged rat sera. (A) The type of supplemented sera did not alter the percentage of total myogenic cells (expressing PAX7, MyoG, or both) (Student’s t -test, t = 1.115, df = 10, p = 0.291). There was no difference in the number (B) and proportions (C) of quiescent, activating and activated myogenic progenitors out of total cells (represented by cells expressing PAX7 + /MyoG − , PAX7 + /MyoG + and PAX7 − /MyoG + , respectively) (2-way ANOVA, F 1,30 = 1.958, p = 0.172 for (B) ; Student’s t -test, t < 0.001 df = 2, p > 0.999 for (C) . (D) On Day 7 of terminal differentiation, cells supplemented with aged rat sera showed an increased level of a cell proliferation marker Ki67 (t = 9.357, df = 10, p < 0.001; by unpaired two-tailed Student’s t-test). (E) Western blot analysis showed increased cyclin B1 and CDK 2 expression in hPSC-derived myogenic progenitors differentiated in 20% aged rat sera for 2 weeks. Beta-actin served as loading control. n = 6 for each group * p < 0.05.

    Techniques Used: Expressing, Derivative Assay, Marker, Two Tailed Test, Western Blot, Control



    Similar Products

    polyclonal antibodies against myog  (Santa Cruz Biotechnology)
    90
    Santa Cruz Biotechnology polyclonal antibodies against myog
    Expression levels of various markers in differentiated hPSC-derived myogenic progenitors treated with rat sera. The expression of Pax7 and Myogenin <t>(MyoG)</t> proteins were analyzed in the differentiated cells for 3 days with 20% young or aged rat sera. (A) The type of supplemented sera did not alter the percentage of total myogenic cells (expressing PAX7, MyoG, or both) (Student’s t -test, t = 1.115, df = 10, p = 0.291). There was no difference in the number (B) and proportions (C) of quiescent, activating and activated myogenic progenitors out of total cells (represented by cells expressing PAX7 + /MyoG − , PAX7 + /MyoG + and PAX7 − /MyoG + , respectively) (2-way ANOVA, F 1,30 = 1.958, p = 0.172 for (B) ; Student’s t -test, t < 0.001 df = 2, p > 0.999 for (C) . (D) On Day 7 of terminal differentiation, cells supplemented with aged rat sera showed an increased level of a cell proliferation marker Ki67 (t = 9.357, df = 10, p < 0.001; by unpaired two-tailed Student’s t-test). (E) Western blot analysis showed increased cyclin B1 and CDK 2 expression in hPSC-derived myogenic progenitors differentiated in 20% aged rat sera for 2 weeks. Beta-actin served as loading control. n = 6 for each group * p < 0.05.
    Polyclonal Antibodies Against Myog, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/polyclonal antibodies against myog/product/Santa Cruz Biotechnology
    Average 90 stars, based on 1 article reviews
    polyclonal antibodies against myog - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier
    rabbit polyclonal antibodies against myog  (Santa Cruz Biotechnology)
    90
    Santa Cruz Biotechnology rabbit polyclonal antibodies against myog
    Expression levels of various markers in differentiated hPSC-derived myogenic progenitors treated with rat sera. The expression of Pax7 and Myogenin <t>(MyoG)</t> proteins were analyzed in the differentiated cells for 3 days with 20% young or aged rat sera. (A) The type of supplemented sera did not alter the percentage of total myogenic cells (expressing PAX7, MyoG, or both) (Student’s t -test, t = 1.115, df = 10, p = 0.291). There was no difference in the number (B) and proportions (C) of quiescent, activating and activated myogenic progenitors out of total cells (represented by cells expressing PAX7 + /MyoG − , PAX7 + /MyoG + and PAX7 − /MyoG + , respectively) (2-way ANOVA, F 1,30 = 1.958, p = 0.172 for (B) ; Student’s t -test, t < 0.001 df = 2, p > 0.999 for (C) . (D) On Day 7 of terminal differentiation, cells supplemented with aged rat sera showed an increased level of a cell proliferation marker Ki67 (t = 9.357, df = 10, p < 0.001; by unpaired two-tailed Student’s t-test). (E) Western blot analysis showed increased cyclin B1 and CDK 2 expression in hPSC-derived myogenic progenitors differentiated in 20% aged rat sera for 2 weeks. Beta-actin served as loading control. n = 6 for each group * p < 0.05.
    Rabbit Polyclonal Antibodies Against Myog, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit polyclonal antibodies against myog/product/Santa Cruz Biotechnology
    Average 90 stars, based on 1 article reviews
    rabbit polyclonal antibodies against myog - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Expression levels of various markers in differentiated hPSC-derived myogenic progenitors treated with rat sera. The expression of Pax7 and Myogenin (MyoG) proteins were analyzed in the differentiated cells for 3 days with 20% young or aged rat sera. (A) The type of supplemented sera did not alter the percentage of total myogenic cells (expressing PAX7, MyoG, or both) (Student’s t -test, t = 1.115, df = 10, p = 0.291). There was no difference in the number (B) and proportions (C) of quiescent, activating and activated myogenic progenitors out of total cells (represented by cells expressing PAX7 + /MyoG − , PAX7 + /MyoG + and PAX7 − /MyoG + , respectively) (2-way ANOVA, F 1,30 = 1.958, p = 0.172 for (B) ; Student’s t -test, t < 0.001 df = 2, p > 0.999 for (C) . (D) On Day 7 of terminal differentiation, cells supplemented with aged rat sera showed an increased level of a cell proliferation marker Ki67 (t = 9.357, df = 10, p < 0.001; by unpaired two-tailed Student’s t-test). (E) Western blot analysis showed increased cyclin B1 and CDK 2 expression in hPSC-derived myogenic progenitors differentiated in 20% aged rat sera for 2 weeks. Beta-actin served as loading control. n = 6 for each group * p < 0.05.

    Journal: Frontiers in Cell and Developmental Biology

    Article Title: Cellular and transcriptomic changes by the supplementation of aged rat serum in human pluripotent stem cell-derived myogenic progenitors

    doi: 10.3389/fcell.2024.1481491

    Figure Lengend Snippet: Expression levels of various markers in differentiated hPSC-derived myogenic progenitors treated with rat sera. The expression of Pax7 and Myogenin (MyoG) proteins were analyzed in the differentiated cells for 3 days with 20% young or aged rat sera. (A) The type of supplemented sera did not alter the percentage of total myogenic cells (expressing PAX7, MyoG, or both) (Student’s t -test, t = 1.115, df = 10, p = 0.291). There was no difference in the number (B) and proportions (C) of quiescent, activating and activated myogenic progenitors out of total cells (represented by cells expressing PAX7 + /MyoG − , PAX7 + /MyoG + and PAX7 − /MyoG + , respectively) (2-way ANOVA, F 1,30 = 1.958, p = 0.172 for (B) ; Student’s t -test, t < 0.001 df = 2, p > 0.999 for (C) . (D) On Day 7 of terminal differentiation, cells supplemented with aged rat sera showed an increased level of a cell proliferation marker Ki67 (t = 9.357, df = 10, p < 0.001; by unpaired two-tailed Student’s t-test). (E) Western blot analysis showed increased cyclin B1 and CDK 2 expression in hPSC-derived myogenic progenitors differentiated in 20% aged rat sera for 2 weeks. Beta-actin served as loading control. n = 6 for each group * p < 0.05.

    Article Snippet: After rinsing with PBS, the cells were incubated with mouse monoclonal antibodies against PAX7 [1:40; Developmental Studies Hybridoma Bank (DSHB), Iowa City, IA] and rabbit polyclonal antibodies against MyoG (1:400; Santa Cruz, Dallas, TX) at 4°C overnight.

    Techniques: Expressing, Derivative Assay, Marker, Two Tailed Test, Western Blot, Control